Physician profile
Pradip Patel
NPI 1215912993
$6,325.61
in general payments reported to CMS, 2019-2025
29 companies · $365 in 2025
The $365 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,448 · 2020: $838 · 2021: $982 · 2022: $1,046 · 2023: $938 · 2024: $709 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,012.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,012.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,195.98 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $677.94 | 2019-2024 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $634.57 | 2019-2024 | Farxiga, Brilinta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $576.95 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $547.12 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $540.47 | 2019-2025 | |
| Pfizer INC. | $354.40 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $303.94 | 2019-2021 | |
| Esperion Therapeutics, INC. | $297.51 | 2021-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $263.09 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $184.20 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $151.14 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $112.63 | 2019-2023 | Verquvo |
| Chiesi USA, INC. | $79.40 | 2021 | |
| Azurity Pharmaceuticals, INC. | $55.36 | 2023-2024 | Edarbi, Edarbi |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $44.93 | 2019-2020 | |
| Astellas Pharma US INC | $38.17 | 2019 | |
| Lundbeck LLC | $36.73 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $35.13 | 2024 | Voquezna |
| Glaxosmithkline, LLC. | $26.86 | 2019 | |
| Gilead Sciences, INC. | $25.37 | 2019 | |
| Angiodynamics, INC. | $21.09 | 2023 | Alphavac |
| Biotronik INC. | $20.60 | 2025 | Biomonitor |
| Inari Medical, INC. | $20.01 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $18.23 | 2023 | Inpefa |
| Kiniksa Pharmaceuticals International, Plc | $17.65 | 2024 | Arcalyst |
| Abbott Laboratories | $17.01 | 2022 | |
| Impulse Dynamics (USA) INC. | $15.05 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $14.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pradip Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.